JP2010535713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535713A5 JP2010535713A5 JP2010519276A JP2010519276A JP2010535713A5 JP 2010535713 A5 JP2010535713 A5 JP 2010535713A5 JP 2010519276 A JP2010519276 A JP 2010519276A JP 2010519276 A JP2010519276 A JP 2010519276A JP 2010535713 A5 JP2010535713 A5 JP 2010535713A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- region
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95374507P | 2007-08-03 | 2007-08-03 | |
| US60/953,745 | 2007-08-03 | ||
| US12362308P | 2008-04-09 | 2008-04-09 | |
| US61/123,623 | 2008-04-09 | ||
| PCT/US2008/072146 WO2009020933A2 (en) | 2007-08-03 | 2008-08-04 | Therapeutic use of anti-tweak receptor antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535713A JP2010535713A (ja) | 2010-11-25 |
| JP2010535713A5 true JP2010535713A5 (enExample) | 2011-09-22 |
| JP5409628B2 JP5409628B2 (ja) | 2014-02-05 |
Family
ID=40193427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519276A Expired - Fee Related JP5409628B2 (ja) | 2007-08-03 | 2008-08-04 | 抗ｔｗｅａｋ受容体抗体の治療上の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9056908B2 (enExample) |
| EP (2) | EP2182982B1 (enExample) |
| JP (1) | JP5409628B2 (enExample) |
| KR (1) | KR20100053607A (enExample) |
| CN (1) | CN102006886A (enExample) |
| BR (1) | BRPI0814768A2 (enExample) |
| CA (1) | CA2694751C (enExample) |
| ES (1) | ES2411907T3 (enExample) |
| IL (1) | IL203038A (enExample) |
| MX (1) | MX2010001378A (enExample) |
| NZ (1) | NZ582815A (enExample) |
| WO (1) | WO2009020933A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2529619T3 (en) | 2005-02-17 | 2016-01-11 | Biogen Ma Inc | Treatment of neurological disorders |
| WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
| BRPI0912198A2 (pt) * | 2008-05-15 | 2019-09-24 | Biogen Idec Inc | anticorpos anti-fn14 e usos dos mesmos |
| ES2363669B1 (es) * | 2009-06-10 | 2012-08-09 | Fundacio Privada Institut D'investigacio Biomedica De Bellvitge (Idibell) | Metodo para determinar el riesgo de desarrollar metastasis cerebral y un kit para llevar a cabo dicho procedimiento |
| CN102675460B (zh) * | 2011-02-28 | 2015-08-19 | 珠海市丽珠单抗生物技术有限公司 | 抗肿瘤坏死因子α的人源化抗体 |
| EP2683740B1 (en) * | 2011-03-10 | 2018-07-04 | Omeros Corporation | Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
| AU2014203658B2 (en) * | 2011-08-23 | 2016-04-28 | La Trobe University | FN14 binding proteins and uses thereof |
| WO2013026099A1 (en) | 2011-08-23 | 2013-02-28 | Transbio Ltd | Fn14 binding proteins and uses thereof |
| WO2013166290A1 (en) | 2012-05-04 | 2013-11-07 | Abbvie Biotherapeutics Inc. | P21 biomarker assay |
| WO2013177386A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Biotherapeutics Inc. | Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy |
| AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| NO2760138T3 (enExample) | 2012-10-01 | 2018-08-04 | ||
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| MX2015016814A (es) | 2013-06-14 | 2016-08-08 | Bayer Pharma AG | Anticuerpo anti-tweakr y sus usos. |
| US9238034B2 (en) * | 2013-07-09 | 2016-01-19 | The Translational Genomics Research Institute | FN14 antagonists and therapeutic uses thereof |
| US9797882B2 (en) | 2013-07-09 | 2017-10-24 | The Translational Genomics Research Institute | Method of screening for a compound for inhibitory activity of FN14-tweak interaction |
| JP6721507B2 (ja) | 2013-12-23 | 2020-07-15 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ） |
| WO2016061632A1 (en) * | 2014-10-23 | 2016-04-28 | La Trobe University | Fn14-binding proteins and uses thereof |
| CA2970565A1 (en) * | 2014-12-15 | 2016-06-23 | Bayer Pharma Aktiengesellschaft | Antibody-drug conjugates (adcs) of ksp inhibitors with aglycosylated anti-tweakr antibodies |
| SG10201908685QA (en) * | 2015-06-22 | 2019-10-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| JP2018525334A (ja) | 2015-06-23 | 2018-09-06 | バイエル ファーマ アクチエンゲゼルシャフト | キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｔｗｅａｋｒ抗体との抗体薬物複合体 |
| CA2990300A1 (en) | 2015-06-23 | 2016-12-29 | Hans-Georg Lerchen | Site specific homogeneous conjugates with ksp inhibitors |
| CA2990411A1 (en) * | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| AU2017236431A1 (en) | 2016-03-24 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| CA3027445A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| EP3558386A1 (de) | 2016-12-21 | 2019-10-30 | Bayer Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| MX2019007641A (es) | 2016-12-21 | 2019-09-09 | Bayer Pharma AG | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. |
| WO2019149637A1 (en) | 2018-01-31 | 2019-08-08 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| US11629179B2 (en) | 2018-06-29 | 2023-04-18 | Stichting Het Nederlands Kanker Instituut—Antoni van Leeuwenhoek Ziekenhuis | TWEAK-receptor agonists for use in combination with immunotherapy of a cancer |
| JP7415939B2 (ja) * | 2018-10-31 | 2024-01-17 | アステラス製薬株式会社 | 抗ヒトＦｎ１４抗体 |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| WO2024105206A1 (en) | 2022-11-17 | 2024-05-23 | Vincerx Pharma Gmbh | Antibody-drug-conjugates cleavable in a tumor microenvironment |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7001992B2 (en) * | 1997-05-30 | 2006-02-21 | Human Genome Sciences, Inc. | Antibodies to secreted protein HEMCM42 |
| DK1015477T3 (da) * | 1997-05-30 | 2011-02-07 | Human Genome Sciences Inc | 32 humane sekreterede proteiner |
| EP0984984A2 (en) * | 1997-06-03 | 2000-03-15 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS |
| WO1999061471A2 (en) | 1998-05-29 | 1999-12-02 | Incyte Pharmaceuticals, Inc. | Human transmembrane proteins |
| AU2507700A (en) | 1999-01-15 | 2000-08-01 | Biogen, Inc. | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| US7495086B2 (en) | 1999-12-20 | 2009-02-24 | Immunex Corporation | TWEAK receptor |
| US6727225B2 (en) * | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
| AU782067B2 (en) * | 1999-12-20 | 2005-06-30 | Immunex Corporation | TWEAK receptor |
| AU4592601A (en) | 2000-03-21 | 2001-10-03 | Millennium Predictive Medicine | Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US7208151B2 (en) * | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
| CA2422095A1 (en) | 2000-09-14 | 2002-03-21 | Biogen, Inc. | Tweak receptor agonists as anti-angiogenic agents |
| WO2002053737A1 (fr) | 2000-12-28 | 2002-07-11 | Asahi Kasei Kabushiki Kaisha | Gene d'activation de nf-kb |
| US20040214167A9 (en) * | 2000-12-28 | 2004-10-28 | Akio Matsuda | NF-kappa B activating gene |
| US7227007B2 (en) * | 2000-12-28 | 2007-06-05 | Asahi Kasei Pharma Corporation | NF-κB activating gene |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| KR100801388B1 (ko) * | 2002-01-02 | 2008-02-05 | 제넨테크, 인크. | 종양의 진단 및 치료 방법 및 이를 위한 조성물 |
| WO2003077939A1 (en) | 2002-03-19 | 2003-09-25 | Genset Sa | Treatment of metabolic disorders with a tnf receptor family member (fradj and/or cryptic) agonists or antagonists |
| AU2003295328A1 (en) | 2002-10-02 | 2004-04-23 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| NZ543751A (en) * | 2003-05-23 | 2008-05-30 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumors of glial origin |
| ATE364050T1 (de) | 2003-07-24 | 2007-06-15 | Amgen Inc | Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak- rezeptors betreffen |
| US7507580B2 (en) * | 2003-10-16 | 2009-03-24 | Zymogenetics, Inc. | Ztnfr14, a tumor necrosis factor receptor |
| US20070298037A1 (en) * | 2003-10-16 | 2007-12-27 | Fox Brian A | ZTNFR14, A Tumor Necrosis Factor Receptor |
| WO2005037865A2 (en) | 2003-10-16 | 2005-04-28 | Zymogenetics, Inc. | Ztnfr14, A TUMOR NECROSIS FACTOR RECEPTOR |
| EP1566636A1 (en) | 2004-02-23 | 2005-08-24 | AXARON Bioscience AG | Use of Tweak modulators and inhibitors for the treatment of neurological conditions |
| WO2005092383A1 (ja) | 2004-03-26 | 2005-10-06 | Takeda Pharmaceutical Company Limited | 呼吸器疾患の予防・治療剤 |
| CN101171035A (zh) * | 2005-03-07 | 2008-04-30 | 健泰科生物技术公司 | 用于调控tweak和fn14活性的方法和组合物 |
| CA2607697C (en) | 2005-05-10 | 2015-01-06 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| WO2006125632A2 (en) | 2005-05-24 | 2006-11-30 | Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh | Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy |
| WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
| WO2006138219A2 (en) * | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
| EP1876448A1 (en) | 2005-09-30 | 2008-01-09 | DIGILAB BioVisioN GmbH | Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones. |
| WO2008140565A2 (en) | 2006-11-08 | 2008-11-20 | Zymogenetics, Inc. | Use of tumor necrosis factor receptor 14 antagonists for treating psoriasis |
| WO2009083950A2 (en) | 2007-12-27 | 2009-07-09 | Compugen Ltd. | Biomarkers for the prediction of renal injury |
| EP2080812A1 (en) | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
-
2008
- 2008-08-04 KR KR1020107004817A patent/KR20100053607A/ko not_active Withdrawn
- 2008-08-04 BR BRPI0814768-0A2A patent/BRPI0814768A2/pt not_active IP Right Cessation
- 2008-08-04 MX MX2010001378A patent/MX2010001378A/es active IP Right Grant
- 2008-08-04 ES ES08797148T patent/ES2411907T3/es active Active
- 2008-08-04 WO PCT/US2008/072146 patent/WO2009020933A2/en not_active Ceased
- 2008-08-04 NZ NZ582815A patent/NZ582815A/en not_active IP Right Cessation
- 2008-08-04 US US12/185,689 patent/US9056908B2/en not_active Expired - Fee Related
- 2008-08-04 JP JP2010519276A patent/JP5409628B2/ja not_active Expired - Fee Related
- 2008-08-04 EP EP08797148A patent/EP2182982B1/en not_active Not-in-force
- 2008-08-04 CA CA2694751A patent/CA2694751C/en not_active Expired - Fee Related
- 2008-08-04 EP EP12175773A patent/EP2545938A1/en not_active Withdrawn
- 2008-08-04 CN CN2008801015223A patent/CN102006886A/zh active Pending
-
2009
- 2009-12-29 IL IL203038A patent/IL203038A/en not_active IP Right Cessation